Sermorelin

What it is

Sermorelin (sermorelin acetate) is a synthetic 29-amino-acid peptide identical to the first 29 amino acids of native human growth hormone-releasing hormone (GHRH). The first 29 residues of the 44-amino-acid native GHRH contain essentially all of the biological activity, making this truncated version pharmacologically equivalent to full-length GHRH.

The brand-name product Geref (sermorelin) was FDA-approved in 1990 for the diagnostic evaluation of growth hormone deficiency in pediatric patients. Commercial production was later discontinued for business reasons unrelated to safety or efficacy. Sermorelin available today is a compounded preparation and is not FDA-approved.

Sermorelin stimulates the pituitary’s own pulsatile GH release rather than supplying growth hormone directly. Its use in adults is off-label, and evidence in adults is limited.

Mechanism of action

Sermorelin binds the GHRH receptor on pituitary somatotrophs (the cells that produce growth hormone), stimulating GH synthesis and pulsatile release. Because it acts on the pituitary rather than replacing GH, several physiologic feedback mechanisms remain in place:

• Pulsatile release: the body releases GH in pulses (typically 4–6 per 24 hours, with the largest pulse during early sleep). Sermorelin enhances the amplitude of natural pulses without producing continuous supraphysiologic GH levels.
• Negative feedback intact: elevated IGF-1 and somatostatin signaling can still modulate GH release in response to sermorelin.
• Pituitary regulation: the pituitary itself limits how much GH is released.

The half-life of sermorelin is short (~10–20 minutes), which is consistent with its role as a pulsatile signal rather than a sustained-action drug.

Research findings

Diagnostic utility: Geref’s original FDA approval rested on robust evidence that it could distinguish hypothalamic GH deficiency (intact pituitary response) from pituitary GH deficiency (no response).

Pediatric GH deficiency treatment: trials in the 1990s and 2000s demonstrated efficacy in supporting linear growth in children with GH deficiency, with growth velocity improvements of 1.5–2x baseline.

Adult studies: smaller body of literature in adults. Studies have demonstrated:

• Increases in GH and IGF-1 levels in adults with documented age-related GH-axis decline
• Small studies on sleep quality and well-being; benefit in adults has not been established

Adult studies are small, and sermorelin has not had the large randomized trials needed for FDA approval in adults.

Side effects and contraindications

Possible side effects:

• Transient flushing or warmth at injection time, typically resolving within minutes
• Mild headache, particularly in the first week
• Injection site irritation
• Joint discomfort or fluid retention if dosing is excessive
• Tingling or numbness in extremities (carpal tunnel-like symptoms) at higher doses
• Vivid or unusual dreams, particularly when first starting

Contraindicated in:

• Active malignancy (any GH-axis stimulant is contraindicated due to GH/IGF-1’s growth-promoting effects)
• Uncontrolled diabetes (GH can worsen insulin resistance)
• Severe obesity (which suppresses GH response and is associated with elevated cardiovascular risk that should not be compounded)
• Pregnancy and breastfeeding
• Known pituitary disease
• Active diabetic retinopathy

What we don’t yet know

Long-term outcomes of sermorelin use in adults are not well characterized in formal studies. The optimal IGF-1 target range for adults seeking GH support — high-normal vs. mid-normal — is debated. Effects on hard outcomes like cardiovascular disease, cognitive trajectory, and longevity itself are not established. Sermorelin may be considered after evaluation for adults with documented age-related GH-axis decline; compounded sermorelin is not FDA-approved.